Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas

A cooperative clinical trial

View More View Less
  • 1 The Brain Tumor Study Group and the National Cancer Institute, National Institutes of Health, Bethesda, Maryland
Restricted access

Purchase Now

USD  $45.00

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $505.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $600.00
Print or Print + Online

✓ A controlled, prospective, randomized study evaluated the use of 1,3-bis(2-chloroethyl)-l-nitrosourea (BCNU) and/or radiotherapy in the treatment of patients who were operated on and had histological confirmation of anaplastic glioma. A total of 303 patients were randomized into this study, of whom 222 (73%) were within the Valid Study Group (VSG), having met the protocol criteria of neuropathology, corticosteroid control, and therapeutic approach. Patients were divided into four random groups, and received BCNU (80 mg/sq m/day on 3 successive days every 6 to 8 weeks), and/or radiotherapy (5000 to 6000 rads to the whole brain through bilateral opposing ports), or best conventional care but no chemotherapy or radiotherapy. Analysis was performed on all patients who received any amount of therapy (VSG) and on the Adequately Treated Group (ATG), who had received 5000 or more rads radiotherapy, two or more courses of chemotherapy, and had a minimum survival of 8 or more weeks (the interval that would have been required to have received either the radiotherapy or chemotherapy). Median survival of patients in the VSG was, best conventional care: 14 weeks (ATG: 17.0 weeks); BCNU: 18.5 weeks (ATG: 25.0 weeks); radiotherapy: 35 weeks (ATG: 37.5 weeks); and BCNU plus radiotherapy: 34.5 weeks (ATG: 40.5 weeks). All therapeutic modalities showed some statistical superiority compared to best conventional care. There was no significant difference between the four groups in relation to age distribution, sex, location of tumor, diagnosis, tumor characteristics, signs or symptoms, or the amount of corticosteroid used. An analysis of prognostic factors indicates that the initial performance status (Karnofsky rating), age, the use of only a surgical biopsy, parietal location, the presence of seizures, or the involvement of cranial nerves II, III, IV, and VI are all of significance. Toxicity included acceptable, reversible thrombocytopenia and leukopenia.

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $505.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $600.00

Contributor Notes

Address reprint requests to: Michael D. Walker, M.D., National Cancer Institute, Building 31, Room 4B32, Bethesda, Maryland 20014.
  • 1.

    Frankel SA, & German WJ: Glioblastoma multiforme. Review of 219 cases with regard to natural history, pathology, diagnostic methods and treatment. J Neurosurg 15:489503, 1958 Frankel SA, German WJ: Glioblastoma multiforme. Review of 219 cases with regard to natural history, pathology, diagnostic methods and treatment. J Neurosurg 15:489–503, 1958

    • Search Google Scholar
    • Export Citation
  • 2.

    Gehan EA: A generalized Wilcoxon test for comparing arbitrarily singly-censored samples. Biometrika 52:203223, 1965 Gehan EA: A generalized Wilcoxon test for comparing arbitrarily singly-censored samples. Biometrika 52:203–223, 1965

    • Search Google Scholar
    • Export Citation
  • 3.

    Gehan EA: Prognostic factors for patients with brain tumors. J Natl Cancer Inst (In press) Gehan EA: Prognostic factors for patients with brain tumors. J Natl Cancer Inst (In press)

    • Search Google Scholar
    • Export Citation
  • 4.

    Goldsmith MA, & Carter SA: Glioblastoma multiforme — a review of therapy. Cancer Treat Rev 1:153165, 1974 Goldsmith MA, Carter SA: Glioblastoma multiforme — a review of therapy. Cancer Treat Rev 1:153–165, 1974

    • Search Google Scholar
    • Export Citation
  • 5.

    Jelsma R, & Bucy PC: The treatment of glioblastoma multiforme of the brain. J Neurosurg 27:388400, 1967 Jelsma R, Bucy PC: The treatment of glioblastoma multiforme of the brain. J Neurosurg 27:388–400, 1967

    • Search Google Scholar
    • Export Citation
  • 6.

    Kaplan EL, & Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457481, 1958 Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481, 1958

    • Search Google Scholar
    • Export Citation
  • 7.

    Karnofsky DA, , Burchenal JH, & Armistead GC Jr, et al: Triethylene melamine in the treatment of neoplastic disease. Arch Intern Med 87:477516, 1951 Karnofsky DA, Burchenal JH, Armistead GC Jr, et al: Triethylene melamine in the treatment of neoplastic disease. Arch Intern Med 87:477–516, 1951

    • Search Google Scholar
    • Export Citation
  • 8.

    Levin VA: A pharmacologic basis for brain tumor chemotherapy. Semin Oncol 2:5761, 1975 Levin VA: A pharmacologic basis for brain tumor chemotherapy. Semin Oncol 2:57–61, 1975

    • Search Google Scholar
    • Export Citation
  • 9.

    Mahaley MS Jr, , Vogel S, & Burger P, et al: Neuropathology observations on tissues from patients treated by the Brain Tumor Study Group (BTSG). J Natl Cancer Inst (In press) Mahaley MS Jr, Vogel S, Burger P, et al: Neuropathology observations on tissues from patients treated by the Brain Tumor Study Group (BTSG). J Natl Cancer Inst (In press)

    • Search Google Scholar
    • Export Citation
  • 10.

    Rubinstein LJ: Tumors of the Central Nervous System. Washington, DC: Armed Forces Institute of Pathology, Second Series, Fascicle 6, 1972 Rubinstein LJ: Tumors of the Central Nervous System. Washington, DC: Armed Forces Institute of Pathology, Second Series, Fascicle 6, 1972

    • Search Google Scholar
    • Export Citation
  • 11.

    Russell DS, & Rubinstein LJ: Pathology of Tumours of the Nervous System, ed 3. London: Edward Arnold, 1970 Russell DS, Rubinstein LJ: Pathology of Tumours of the Nervous System, ed 3. London: Edward Arnold, 1970

    • Search Google Scholar
    • Export Citation
  • 12.

    Schabel FM Jr, , Johnston TP, & McCaleb GS, et al: Experimental evaluation of potential anticancer agents. VIII. Effects of certain nitrosoureas on intracerebral L1210 leukemia. Cancer Res 23:725733, 1963 Schabel FM Jr, Johnston TP, McCaleb GS, et al: Experimental evaluation of potential anticancer agents. VIII. Effects of certain nitrosoureas on intracerebral L1210 leukemia. Cancer Res 23:725–733, 1963

    • Search Google Scholar
    • Export Citation
  • 13.

    Snedecor G, & Cochran WG: Statistical Methods, ed 6. Ames, Iowa: Iowa State University Press, 1967, pp 215220 Snedecor G, Cochran WG: Statistical Methods, ed 6. Ames, Iowa: Iowa State University Press, 1967, pp 215–220

    • Search Google Scholar
    • Export Citation
  • 14.

    Vendetti JM, , Kline I, & Goldin A: Evaluation of antileukemic agents employing advanced leukemia L1210 in mice. VIII. Cancer Res 24 (Suppl) No. 6, Part 2:827879, 1964 Vendetti JM, Kline I, Goldin A: Evaluation of antileukemic agents employing advanced leukemia L1210 in mice. VIII. Cancer Res 24 (Suppl) No. 6, Part 2:827–879, 1964

    • Search Google Scholar
    • Export Citation
  • 15.

    Walker MD: Brain and peripheral nervous system tumors, in Holland JF, & Frei E III (eds): Cancer Medicine. Philadelphia: Lea and Febinger, 1973, pp 13851407 Walker MD: Brain and peripheral nervous system tumors, in Holland JF, Frei E III (eds): Cancer Medicine. Philadelphia: Lea and Febinger, 1973, pp 1385–1407

    • Search Google Scholar
    • Export Citation
  • 16.

    Walker MD, , Alexander E Jr, & Hunt WE, et al: The evaluation of mithramycin in the treatment of anaplastic gliomas. J Neurosurg 44:655667, 1976 Walker MD, Alexander E Jr, Hunt WE, et al: The evaluation of mithramycin in the treatment of anaplastic gliomas. J Neurosurg 44:655–667, 1976

    • Search Google Scholar
    • Export Citation
  • 17.

    Walker MD, & Hurwitz BS: BCNU 1,3-bis(2-chloroethyl)-1-nitrosourea; (NSC-409962) in the treatment of malignant brain tumor — a preliminary report. Cancer Chemother Rep 54:263271, 1970 Walker MD, Hurwitz BS: BCNU 1,3-bis(2-chloroethyl)-1-nitrosourea; (NSC-409962) in the treatment of malignant brain tumor — a preliminary report. Cancer Chemother Rep 54:263–271, 1970

    • Search Google Scholar
    • Export Citation
  • 18.

    Walker MD, & Strike TA: An evaluation of Methyl-CCNU, BCNU and radiotherapy in the treatment of malignant glioma. Proc Am Assoc Cancer Res 17:163, 1976 (Abstract) Walker MD, Strike TA: An evaluation of Methyl-CCNU, BCNU and radiotherapy in the treatment of malignant glioma. Proc Am Assoc Cancer Res 17:163, 1976 (Abstract)

    • Search Google Scholar
    • Export Citation
  • 19.

    Wilson CB, , Boldrey EB, & Enot KJ: 1,bis(2-chloroethyl)-1-nitrosourea (NSC-409962) in the treatment of brain tumors. Cancer Chemother Rep 54:273281, 1970 Wilson CB, Boldrey EB, Enot KJ: 1,bis(2-chloroethyl)-1-nitrosourea (NSC-409962) in the treatment of brain tumors. Cancer Chemother Rep 54:273–281, 1970

    • Search Google Scholar
    • Export Citation

Metrics

All Time Past Year Past 30 Days
Abstract Views 1596 827 63
Full Text Views 1750 162 6
PDF Downloads 367 113 5
EPUB Downloads 0 0 0